WebDoctor Encyclopedia

Ovarian

Malignant Brenner tumour of the ovary

A malignant Brenner tumour is a rare ovarian cancer with bladder-like cells that grows from a benign or borderline Brenner tumour. It usually affects older women, is often found at stage I, and has an excellent outlook when confined to the ovary.

Medically reviewed Last reviewed October 21, 2026

What is a malignant Brenner tumour of the ovary?

A malignant Brenner tumour is a rare type of ovarian cancer. Its cells look like the lining of the bladder (urothelium), which is why it is also called a transitional-type tumour. It accounts for less than 1% of all ovarian cancers (Koufopoulos et al., 2024).

Brenner tumours come in three forms. Most are benign and are often found by chance during surgery for something else. A smaller number are borderline, meaning they have some abnormal features but do not invade. The malignant form is the rarest, and it usually grows from a pre-existing benign or borderline Brenner tumour (Turashvili and Hanley, 2025).

Malignant Brenner tumours usually affect women after the menopause. They are often large, one-sided tumours that are still confined to the ovary when found. In that situation, the outlook is very good.

How it differs from common ovarian cancer

The most common ovarian cancers are high-grade serous carcinomas, covered with other types on our page on epithelial ovarian cancer. Malignant Brenner tumour behaves quite differently.

Feature High-grade serous carcinoma Malignant Brenner tumour
Share of ovarian cancers The majority Less than 1%
Typical stage at diagnosis Advanced, with spread in the abdomen More than half at stage I
Sides affected Often both ovaries Usually one ovary
Origin Usually the fallopian tube Benign or borderline Brenner tumour
Benign component Absent Present in the same tumour
Outlook Often guarded Excellent when confined to the ovary

1. Key facts at a glance

Feature Details
Type of cancer Rare epithelial ovarian cancer with bladder-like (transitional) cells
How common Under 1% of malignant ovarian tumours
Typical age Usually after menopause; median 65 years in a US database
Size Often large; median about 10 cm
Sides Usually one ovary
Main treatment Surgery to remove the tumour and stage the disease
Other treatment Platinum chemotherapy for spread or high risk
Outlook Very good if limited to the ovary; poorer with spread

2. Types

The Brenner tumour family

Type Behaviour Notes
Benign Brenner tumour Harmless Most common; often small and found by chance
Borderline Brenner tumour Low malignant potential Abnormal cells without invasion
Malignant Brenner tumour Cancer Invasive nests of tumour cells next to benign or borderline areas

What is not a malignant Brenner tumour

In the past, some ovarian cancers that looked transitional but had no benign Brenner component were called “transitional cell carcinoma of the ovary”. Today most of these are classified as a pattern of high-grade serous carcinoma. To be called a malignant Brenner tumour, the cancer must arise next to a benign or borderline Brenner tumour.

3. Causes and risk factors

Factor Notes
Age Mainly women in their 50s to 70s
Pre-existing Brenner tumour Thought to be the starting point
Walthard nests Small clusters of bladder-like cells on the tubes and ovaries, possibly the origin of Brenner tumours
Mucinous tumours Brenner tumours often occur together with mucinous cystadenomas
Inherited factors No inherited syndrome is known

A US hospital review of benign Brenner tumours found Walthard nests close by in most cases and noted their association with mucinous cystadenomas (Alloush et al., 2023). These findings support the idea that Brenner tumours arise from transitional-type cells near the junction of the tube and ovary.

Why do benign tumours sometimes turn malignant?

Experts believe Brenner tumours progress step by step. A benign tumour may gain genetic changes that make it borderline, and further changes may then allow it to invade. Small studies have reported changes in cell-cycle genes such as CDKN2A in some malignant cases. Most benign Brenner tumours, however, never change, so finding one is not a reason for alarm.

4. How does it look

On scans

Scan Typical findings
Pelvic ultrasound A large mass, solid or mixed solid and cystic
CT Solid areas, sometimes with chunky calcification
MRI Solid parts often look dark on T2-weighted images because of fibrous tissue
CT of chest and abdomen Checks for spread

At surgery

Finding Description
Size Often more than 10 cm
Appearance Solid and cystic; cut surface may be firm and gritty
Sides Usually one ovary
Spread Absent in most women; when present, often to the pelvis and abdomen

Under the microscope

Feature Description
Benign part Nests of bland bladder-like cells in fibrous tissue
Malignant part Irregular, invading nests or sheets of abnormal transitional or squamous-like cells
Stains GATA3 and p63 often positive; WT1 negative
Sampling The pathologist must examine many areas to find all components

A careful review stresses that wide sampling and stains are needed so the tumour is not mistaken for other ovarian cancers or for spread from the bladder (Turashvili and Hanley, 2025).

5. Symptoms

Many women have few symptoms until the tumour is large.

Common symptoms

  • Swelling or bloating of the abdomen
  • Pain or pressure in the pelvis or lower abdomen
  • A lump that can be felt in the lower abdomen
  • Needing to pass urine more often

Less common symptoms

Symptom Possible cause
Vaginal bleeding after menopause Occasionally reported; may reflect hormone activity in the tumour
Constipation Pressure on the bowel
Feeling full quickly Pressure or fluid in the abdomen
Fluid in the abdomen (ascites) More advanced disease
Weight loss and tiredness Advanced disease

When to seek medical advice

See a doctor if you have persistent bloating, pelvic pain, feeling full quickly or needing to pass urine more often, especially if these occur most days for more than three weeks.

6. Diagnosis

Step What is done
Examination Abdominal and pelvic examination
Pelvic ultrasound First test for an ovarian mass
CA-125 blood test May be raised; helps assess risk
CT or MRI Further imaging and staging
Surgery Removal of the mass for diagnosis
Pathology Confirms all components and excludes other cancers
Bladder check Sometimes advised to exclude spread from a bladder cancer

Why the diagnosis is usually made after surgery

Scans can show that an ovarian mass looks suspicious, but they cannot tell which type of tumour it is. Needle biopsies of ovarian masses are usually avoided when the tumour seems confined to the ovary, because puncturing it could spread cells into the abdomen. The whole tumour is therefore removed, and the final diagnosis comes from the pathology report, typically one to two weeks later.

Staging

Malignant Brenner tumour is staged with the FIGO system for ovarian cancer.

Stage Simplified meaning Share in a US database
Stage I Limited to one or both ovaries About 55%
Stage II Spread within the pelvis About 14%
Stage III Spread to the abdomen or lymph nodes About 18%
Stage IV Distant spread About 12%

These figures come from a study of 207 women in the US SEER database (Nasioudis et al., 2016).

7. Treatment

Treatment is planned by a gynaecological oncology team. Because the tumour is rare, there are no trials specific to it, and care is based on case series and general ovarian cancer principles.

Surgery

Procedure Purpose
Removal of the womb, both ovaries and tubes Standard for most women
Removal of the omentum Checks for hidden spread
Washings and peritoneal biopsies Staging
Lymph node removal Debated; see below
Fertility-sparing surgery Rarely relevant, as most women are past menopause
Debulking surgery Removes as much visible tumour as possible in advanced disease

Lymph node removal

Studies disagree. In the SEER study, lymph node spread was rare, at about 5%, and removing nodes was not linked to better survival (Nasioudis et al., 2016). A systematic review of 115 published cases found better disease-specific survival in women who had lymph node removal (Koufopoulos et al., 2024). Surgeons weigh these findings for each woman.

Chemotherapy

Situation Approach
Stage IA, completely removed Often no chemotherapy
Higher-stage or high-risk stage I Carboplatin and paclitaxel commonly used
Recurrence Further chemotherapy, surgery in selected cases, or clinical trials

Side effects

Treatment Possible side effects
Surgery Pain, wound problems, bowel or bladder changes; early menopause if not yet reached
Carboplatin Low blood counts, tiredness, sickness
Paclitaxel Hair loss, numbness in hands and feet, joint aches

8. Outlook (prognosis)

Situation Five-year disease-specific survival
Tumour confined to the ovary About 95%
Spread beyond the ovary About 51%

These figures come from Nasioudis et al. (2016). A recent review reported recurrence in nearly half of the published cases with follow-up, and deaths from disease in at least one in five (Turashvili and Hanley, 2025). Published cases may overrepresent difficult tumours, so these numbers should be read with care.

Factors that affect the outlook

Factor Effect
Stage The most important factor
Ascites Linked to more recurrences
Raised CA-125 Linked to more recurrences
Complete removal Better outlook

The systematic review found recurrences more often in women with ascites or raised CA-125 (Koufopoulos et al., 2024).

9. Follow-up

Period Typical checks
Years 1-2 Every 3-4 months: symptoms, examination and CA-125 if it was raised
Years 3-5 Every 6 months
After 5 years Yearly or as advised

Scans are done if symptoms or blood tests suggest a recurrence.

10. Living with a malignant Brenner tumour

  • Recover gradually after major surgery, avoiding heavy lifting for several weeks
  • Report new bloating, pain or bowel changes
  • Ask about menopause symptoms and bone health if surgery caused early menopause
  • Keep active and eat a balanced diet
  • Seek support from ovarian cancer charities

Life after treatment

Most women with stage I disease return to their usual activities within a few months. Tiredness can last longer, especially after chemotherapy. Gentle exercise, a regular sleep routine and pacing activities through the day all help. Tell your team if low mood, anxiety or fear of recurrence are affecting daily life.

Recovery after surgery

Period What to expect
First days Pain control, walking soon after surgery, wound care
2-6 weeks Gradual return to light activities
6-8 weeks Most women can drive and return to many normal activities
If chemotherapy follows Usually starts within 4-6 weeks

Coping with an uncommon diagnosis

Because this cancer is so rare, you may find little information about it online, and some of what you find may refer to other ovarian cancers. Your gynaecological oncology nurse specialist can explain how your situation compares and point you to reliable sources. Ovarian cancer charities offer helplines, support groups and information about life after treatment.

11. Frequently asked questions

Question Answer
Is a Brenner tumour always cancer? No; most Brenner tumours are benign
How was it found? Often as a large pelvic mass on an ultrasound done for pain, bloating or another reason
Is it related to bladder cancer? No; the cells look similar, but it is a primary ovarian tumour
Is it inherited? No inherited link is known
Do I need chemotherapy? Not always; it depends on stage and other risk factors
Will I need my lymph nodes removed? It depends on your surgeon’s assessment; studies disagree on benefit
Can I have hormone replacement therapy? Often yes; discuss it with your oncologist, as the decision depends on your situation
Can it come back? Yes, especially with advanced disease, so follow-up is important

12. Questions to ask your care team

  • Was the tumour confined to the ovary?
  • Did the pathologist find a benign or borderline Brenner component?
  • What stage is the cancer?
  • Do I need chemotherapy?
  • Were my lymph nodes removed, and why?
  • How will I be followed up?
  • What symptoms should prompt me to call you?
  • Is there a specialist nurse I can contact?
  • Would a second pathology opinion be useful for such a rare tumour?

Resources

  1. Alloush, F. et al. (2023) ‘Brenner tumor of the ovary: a 10-year single institution experience and comprehensive review of the literature’, Medical Sciences, 11(1), 18.
  2. Koufopoulos, N.I. et al. (2024) ‘Malignant Brenner tumor of the ovary: a systematic review of the literature’, Cancers, 16(6), 1106.
  3. Nasioudis, D. et al. (2016) ‘Malignant Brenner tumors of the ovary; a population-based analysis’, Gynecologic Oncology, 142(1), pp. 44-49.
  4. Turashvili, G. and Hanley, K. (2025) ‘Malignant Brenner tumor of the ovary: a critical reappraisal’, International Journal of Gynecological Pathology, 44(2), pp. 182-192.
  5. National Cancer Institute (2026) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.